Abstract
Androgen deprivation therapy has been the standard treatment for the patients with advanced prostate cancer. Androgen deprivation therapy initially suppresses the growth of prostate cancer. However, most patients eventually progress to castration-resistant prostate cancer. Novel drugs, including enzalutamide and abiraterone acetate, are recently able to be used for the patients with castration-resistant prostate cancer. Even so, the therapeutic options for castration-resistant prostate cancer are not enough. Interestingly, androgen receptor degradation enhancer ASC-J9 is reported to degrade the androgen receptor, resulting in the suppression of the growth in castration-resistant prostate cancer cells. In this chapter, ASC-J9 for prostate cancer is reviewed.
| Original language | English |
|---|---|
| Pages (from-to) | 2126-2129 |
| Number of pages | 4 |
| Journal | Nihon rinsho. Japanese journal of clinical medicine |
| Volume | 72 |
| Issue number | 12 |
| Publication status | Published - 2014 Dec 1 |
ASJC Scopus subject areas
- Medicine(all)
